The U.S. Food and Drug Administration did not approve Polarean Imaging’s application for a new drug-device combination product, sending the company’s shares tumbling 60 percent.

In a roundup of scientific studies on the novel coronavirus, new findings shed light on why chronic lung diseases that block the airways increase patients’ risks for severe Covid-19 and researchers say the blood disorder anemia should probably be added to the list of risk factors for poorer Covid-19 outcomes.

Galapagos and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet the study’s primary endpoint in osteoarthritis knee repair.

French researchers are developing what they say is the most powerful Magnetic Resonance Imaging (MRI) scanner in the world, which will use a supermagnet the weight of a blue whale and should allow earlier diagnosis of diseases such as Parkinson’s.

Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.

What if we could look inside the minds of HCPs to see what is happening there during industry events and interactions?

Royal Philips, a global leader in health technology, and Hologic Inc., an innovative women’s health company, announced today a global partnership agreement to offer care professionals integrated solutions comprising diagnostic imaging modalities, advanced informatics and services for screening, diagnosis and treatment of women across the world.

Consumers who search online for prices of common medical procedures may be disappointed by what they find, a U.S. study suggests.

Stimwave LLC received FDA 510(k) clearance for the first wireless, micro-technology neuromodulation device that can enable ongoing full-body MRI scans under certain scanning conditions for the relief of chronic peripheral nerve pain.

Boston Scientific called a single pacemaker-related death for its S-ICD implant a “fluke” that was the result of radiation corruption that negatively impacted the device’s memory.